|Bid||25.2100 x 200|
|Ask||25.2400 x 600|
|Day's Range||24.7600 - 27.0100|
|52 Week Range||10.0400 - 29.5000|
|PE Ratio (TTM)||125.38|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Exelixis, Illumina, and Veeva Systems. Expensive, but worth it?
Exelixis is on a roll. Exelixis (EXEL) was on the ropes only three years ago after its lead candidate, cabozantinib, failed in a Phase 3 trial to treat men with metastatic castration-resistant prostate cancer (mCRPC). Exelixis reached a licensing pact with Ipsen (IPSEY) in 2016.